Moderna could be sued over vaccines as court upholds Arbutus patents
https://www.reuters.com/business/healthcare-pharmaceuticals/moderna-loses-appeal-challenging-arbutus-vaccine-patents-2021-12-01/
Dec 1 (Reuters) - Moderna Inc (MRNA.O) could face a patent infringement lawsuit over its COVID-19 vaccine after a federal appeals court on Wednesday rejected its challenge to patents belonging to Arbutus Biopharma Corp (ABUS.O).
Arbutus shares nearly doubled following the ruling, up 95% at $6.25. Moderna shares were off more than 10% at $316.43.
The Federal Circuit U.S. Court of Appeals let stand an administrative panel's findings that Arbutus' patents - which may cover technology used in the vaccines - are valid, as the science involved was not previously known.
Moderna and Arbutus did not respond to requests for comment.
Moderna previously said in court filings that it believes Arbutus could bring a lawsuit demanding royalties from its COVID-19 vaccine if the patents were upheld.
The company last month forecast 2021 sales of between $15 billion and $18 billion, and 2022 sales of between $17 billion and $22 billion, for its COVID-19 vaccine.